Syndrome  >>  Soliris (eculizumab)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

7 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Soliris (eculizumab) / AstraZeneca
NCT00112983: Eculizumab in Treating Patients With Paroxysmal Nocturnal Hemoglobinuria

Completed
3
US
eculizumab
Jonsson Comprehensive Cancer Center
Leukemia
 
06/05
NCT00122330: Study Using Eculizumab in Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients

Completed
3
75
US, Canada, Europe, RoW
eculizumab
Alexion Pharmaceuticals
Hemoglobinuria, Paroxysmal
 
01/06
NCT00098280: Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria

Completed
3
75
US
Eculizumab
National Heart, Lung, and Blood Institute (NHLBI)
Hemoglobinuria, Paroxysmal
 
02/06
NCT00122304 / 2004-002795-42: Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab

Completed
3
85
US, Canada, Europe, RoW
eculizumab
Alexion Pharmaceuticals
Hemoglobinuria, Paroxysmal
 
11/06
NCT00130000: Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria

Completed
3
87
US
Eculizumab
National Heart, Lung, and Blood Institute (NHLBI)
Paroxysmal Hemoglobinuria, Nocturnal
 
06/07
NCT00122317 / 2005-000043-28: Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)

Completed
3
187
US, Canada, Europe, RoW
eculizumab, Soliris
Alexion Pharmaceuticals
Paroxysmal Hemoglobinuria, Nocturnal
09/08
10/08
STEC-HUS, NCT01410916 / 2011-002691-17: Safety and Efficacy Study of Eculizumab in Shiga-Toxin Producing Escherichia Coli Hemolytic-Uremic Syndrome

Completed
2/3
198
Europe
Eculizumab (Soliris®)
Alexion Pharmaceuticals
Shiga-like Toxin-producing Escherichia Coli
01/12
06/12

Download Options